Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumor indications. The company's MultiTAA-specific T cell technology involves the development of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing these antigens. Their product portfolio includes autologous and allogeneic T cell therapies for lymphoma, solid tumors, acute myeloid leukemia, and acute lymphoblastic leukemia, as well as peptide-based immunotherapeutic vaccines for breast and ovarian cancer cells. Marker Therapeutics generates revenue through the development and commercialization of these innovative immunotherapies and vaccines.

Products

• T cell-based immunotherapies

• Peptide-based vaccines